[Dilren efficacy in postmyocardial infarction patients].
25 survivors of primary macrofocal myocardial infarction (MI) were treated for a year with children. The response in 9(36%) patients was achieved with a single dose 180 mg, in 16(64%) patients with concomitant arterial hypertension the dose was raised to 300 mg. No fatal outcomes were registered. Repeated IM developed in 4(16%) patients. 15(60%) patients improved, deterioration was seen in 4(16%) patients. Dilren-induced complications occurred in 3(12%) patients.